Q3 2020 13F Holders as of 30 Sep 2020
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
129M
-
Number of holders
-
19
-
Total 13F shares, excl. options
-
720K
-
Shares change
-
+423K
-
Total reported value, excl. options
-
$1.74M
-
Value change
-
+$1.02M
-
Put/Call ratio
-
0.54
-
Number of buys
-
14
-
Number of sells
-
-3
-
Price
-
$2.42
Significant Holders of ATOSSA THERAPEUTICS, INC. - Common Stock (ATOS) as of Q3 2020
23 filings reported holding ATOS - ATOSSA THERAPEUTICS, INC. - Common Stock as of Q3 2020.
ATOSSA THERAPEUTICS, INC. - Common Stock (ATOS) has 19 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 720K shares
of 129M outstanding shares and own 0.56% of the company stock.
Largest 10 shareholders include VANGUARD GROUP INC (209K shares), MORGAN STANLEY (131K shares), GEODE CAPITAL MANAGEMENT, LLC (89.9K shares), RENAISSANCE TECHNOLOGIES LLC (74.5K shares), SUSQUEHANNA INTERNATIONAL GROUP, LLP (51.1K shares), TWO SIGMA INVESTMENTS, LP (41.9K shares), CITADEL ADVISORS LLC (24.5K shares), GOLDMAN SACHS GROUP INC (21.3K shares), Federation des caisses Desjardins du Quebec (17.6K shares), and SUSQUEHANNA FUNDAMENTAL INVESTMENTS, LLC (16.9K shares).
This table shows the top 19 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.